VT 111

Drug Profile

VT 111

Alternative Names: Serine protease inhibitor-1; SERP-1; VT-111; VT-111a; VT-111b

Latest Information Update: 16 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viron Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Serpins
  • Mechanism of Action Immunosuppressants; Peptide hydrolase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute coronary syndromes

Highest Development Phases

  • No development reported Acute coronary syndromes; Transplant rejection
  • Discontinued Atherosclerosis; Coronary artery restenosis; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 07 Sep 2015 No recent reports on development identified - Phase-II for Acute coronary syndromes in USA and Canada (IV)
  • 07 Sep 2015 No recent reports on development identified - Preclinical for Transplant rejection (Prevention) in Canada (IV)
  • 20 Dec 2010 VT 111 is available for licensing for cardiac stenting (\www.vironinv.com\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top